Erin Neil-Knierbein
Neuromuscular Medicine · Ann Arbor, MINPI 1073718946
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $175 of the $175 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Novartis Gene Therapies, Inc. (fka Avexis, Inc.).
Across 3 payments — averaging $58.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$175
Across 141 payments — averaging $3884.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- PTC Therapeutics, Inc.$280K
- Janssen Research & Development, LLC$110K
- Hoffmann-la Roche Limited$79K
- Sarepta Therapeutics, Inc.$64K
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$16K
What the payments were for
- Speaking & faculty fees$175100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 3 | $175 |
How this compares
Too few neuromuscular medicine providers in Michiganto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exondys-51Eteplirsen | 15 | $2,935,914 |
Paid to pharmacies, not to this prescriber.
Other neuromuscular medicine in Ann Arbor
- Swathi Beladakere RamaswamyAnn Arbor$1K
- Aiesha AhmedGrand Rapids$36K
- John TegtmeierEast Lansing$2K
- Mark BrennanClinton Township$334
- Rachel BassGrand Rapids$330
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.